Related Experiment Videos
Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b
S Markovic-Plese1, B Bielekova, N Kadom
1Neuroimmunology Branch, National Institute of Neurological Diseases and Stroke, NIH, Bethesda, MD 20892-1400, USA.
Neurology
|June 11, 2003
Abstract:
An open-label study was performed to assess the effectiveness of oral azathioprine (AZA) on augmenting the response to interferon beta-1b (IFNbeta-1b) in patients with treatment-refractory relapsing-remitting MS. Six IFNbeta-1b-treated MS patients with continued disease activity were studied on IFNbeta-1b and AZA therapy for a median period of 15 months. A 69% reduction in the number of contrast-enhancing lesions was observed during the combination therapy (p = 0.002).